These references date back to the beginning of this website, put online in June 1999 by Wendy Sheridan. There have since been many updates within the pages of this site, with new references appearing on each individual page as the information is added.

About bladder cancer

   Ta, T1 Bladder Cancer: What Can We Learn From EORTC Trials? APM van der Meijden Department of Urology, Bosch Medicentrum, Den Bosch, The Netherlands

2. Memorial Sloan Kettering website;
   http://www.mskcc.org/document/WICBLAD.htm

   Bladder Cancer: State of the Art Care Michael J Droller, M.D.

4. http://www.duj.com/Article/Streem.htmlEnodourologic Management of Upper Tract Transitional Cell Carcinoma Peter E. Clark, M.D. Stevan B. Streem, M.D. Cleveland Clinic Foundation, Department of Urology Cleveland Ohio

5. http://www.ca-journal.org/articles/46/2/093-112/46_093-112_frame.htm As reviewed by Dr. DL Lamm and Dr. Frank M. Torti Bladder Cancer 1996

   #UndifferentiatedCarcinoma


Staging and grading
1. A proposed simplified staging system of invasive bladder tumors. Herr HW
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Urol Int 1993;50(1):17-20
PMID: 8434421 UI: 93166596

2. Ta, T1 Bladder Cancer: What Can We Learn From EORTC Trials? APM van der Meijden
Department of Urology, Bosch Medicentrum, Den Bosch, The Netherlands
http://www.urol-int.org/Sep97/Clinical/clinical.htm Urology International

3. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy.
Soloway MS; Lopez AE; Patel J; Lu Y Department of Urology, University of Miami School of Medicine, Florida. Cancer 1994 Apr 1;73(7):1926-31
PMID: 8137219 UI: 94184931

Diagnostic procedures

1. Evaluation of new resectoscope loop for transurethral resection of bladder tumors. Herr HW; Reuter VE
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.


Non Muscle-invasive Bladder Cancer

1. References as reviewed in Bladder Cancer: State of the Art Care by Michael J. Droller, M.D;

Bladder carcinoma as a systemic disease. Cancer 1979;43:2532-2539. Prout GR Jr, Griffin PP, Shipley WU:


Professor G. Steineck, Karolinska Hospital, Stockholm, Sweden, unpublished data.


6. http://www.duj.com/Article/Schenkman.htmlSuperficial Bladder Cancer Therapy References as reviewed by Drs. Emmanuel Schenkman, M.D. and Donald L. Lamm, M.D.


7. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same!

8. Transitional Cell Papilloma: Revisiting An Old Concept
William M. Murphy Department of pathology, Immunology and Laboratory Medicine,
University of Florida College of Medicine, Gainesville, Fla. USA
http://www.urol-int.org/Oct96/Winds/winds.htm

9. Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group

Intravesical chemotherapy

1. Congress held in Turkey in 1996, Dr. A. van der Meijden from the Netherlands reviewed "Future of Urological Oncology in Clinical and Basic Research through European Collaboration

2. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer Pawinski A; Sylvester R; Kurth KH; Bouffioux C; van der Meijden A; Parmar MK; Bijnens L Department of Urology, Memorial Cancer Center, Warsaw, Poland. J Urol 1996 Dec; 156(6):1934-40, discussion 1940-1 PMID: 8911360 UI: 97068032


8. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A. Department of Pathology, Faculty of Medicine, Mansoura University, Egypt J Urol 1997 Jul;158(1):68-73; discussion 73-4 PMID: 9186325 UI: 97329866
Reviewed by Prof. Dr. Jakse on: www.Uroweb.nl http://www.uroweb.nl/bladderweb/literature/review3/body.shtml

As reviewed in the article: Intravesical Therapy for Superficial Bladder Cancer Ashish M. Kamat, MD, Donald L. Lamm, MD West Virginia School of Medicine, Morgantown, W. Va. March, 1999 (From "Infections in Urology) www.medscape.com

Additional Source;

http://www.duj.com/Article/Schenkman.html Superficial Bladder Cancer Therapy Emmanuel Schenkman, M.D. and Donald L. Lamm, M.D. Schenkman and Lamm's review of the latest statistics and treatments for management of superficial bladder cancer in the Digital Urology Journal (year?)

Immunotherapy
BCG

1. Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA. Department of Surgery, Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Urology 1998 Aug;52(2):268-75; discussion 275-6 PMID: 9697793 UI: 98361258


5. Future of Urological Oncology in Clinical and Basic Research through European Collaboration www.uroweb.nl Congress held in Turkey in 1996, a talk by Dr. A. van der Meijden from the Netherlands


References 6 and 7 as reviewed by Drs. Emmanuel Schenkman, M.D. and Donald L. Lamm, M.D.; http://www.duj.com/Article/Schenkman.htmlSuperficial Bladder Cancer Therapy

8. Complications of bacille Calmette-Guerin (BCG) vaccination and immunotherapy and their management.
J Grange; Commun Dis Public Health. 1998 Jun;1PMID: 9644119 UI: 98299079

9. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM J Urol 1985 Jul;134(1):48-53
PMID: 3892051 UI: 85237760

10. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. Department of Urology, Medical University of Lubeck, Germany. Bohle A; Rusch-Gerdes S; Ulmer AJ; Braasch H; Jocham DJ Urol 1996 Jun;155(6):1892-6
PMID: 8618281 UI: 96212478

Interferon

1. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. Torti FM; Shortliffe LD; Williams RD; Pitts WC; Kempson RL; Ross JC; Palmer J; Meyers F; Ferrari M; Hannigan J; et al
Stanford University Medical Center, Palo Alto, CA


Belldegrun AS; Franklin JR; O'Donnell MA; Gomella LG; Klein E; Neri R; Nseyo UO; Ratliff TL; Williams RD
Division of Urologic Oncology, UCLA School of Medicine, Los Angeles, California, USA.

4. IFN-alpha 2B Enhances Th1 Cytokine Responses in Bladder Cancer Patients Receiving Mycobacterium bovis Bacillus Calmette-Guerin Immunotherapy Authors: Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA Harvard Medical School, Boston PMID: 0073521 UI: No Cit. ID assigned 3:98-101.

Keyhole Limpet Hemocyanin


PMID: 4810758 UI: 74085192

4. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer. Lamm DL; DeHaven JI; Riggs DR; Delgra C; Burrell R

Department of Urology, West Virginia University School of Medicine, Morgantown 26506. Urol Res 1993 Jan;21(1):33-7 PMID: 8456536 UI: 93206415

5. Editorial comment by DL Lamm, following article: Recurrent superficial transition cell carcinoma of the bladdera: Adjuvant topical chemotherapy versus immunotherapy a prospective randomized trial Department of Urology, Wilhelminenspital, Hanuschkrankenhaus and Rudolfsftting, Vienna, Austria J Urol 1990 Aug;144(2 Pt 1):260-3 PMID: 2197428 UI: 90325324


Bropirimine

1. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Sarosdy MF; Manyak MJ; Sagalowsky AI; Beldegrun A; Benson MC; Bihrl W; Carroll PR; Ellis WJ; Hudson MA; Sharkey FE Department of Urology, University of Texas Health Science Center, San Antonio, USA. Urology 1998 Feb;51(2):226-31 PMID: 9495702 UI: c


PDT


2. Photodynamic Therapy Using Porfiner Sodium as an Alternative to Cystectomy in Patients with Refractory Transitional Cell Carcinoma in Situ of The Bladder Photofrin Study Group Nseyo UO; Shumaker B; Klein EA; Sutherland K
3. Long term experience with photodynamic therapy (PDT) in the management of superficial vesical transitional cell carcinoma (SVTCC) (Meeting abstract). - Nseyo U; Lamm D; Riggs D; DeHaven J; Dougherty T; Porter W; Lundahl S; Merrill D WVU Medical School, Morgantown/Clarksburg, WV Proc Annu Meet Am Assoc Cancer Res 1997;38:A2524 UI - 98639524


Combined modalities

1. The status of bladder-preserving therapeutic strategies in the management of patients with muscle-invasive bladder cancerKoiso K; Shipley W; Keuppens F; Baert L; Hall R; Hudson MA; Khoury S; Kubota Y; Kubota Y; van Poppel H University of Tsukuba Institute of Clinical Medicine, Department of Urology, Ibaraki, Japan.


5. Combined-Modality Therapy for Bladder Cancer McCaffrey JA, Bajorin DF, Scher HI, Bosl GJ Department of Medicine, Memorial Sloan Kettering Cancer Center, NY NY PMID:9330404 UI: 97471463 Oncology 11(9Suppl ()::18-26, 1997 Sep

6. Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study Chauvet B; Felix-Faure C; Davin JL; Berger C; Vincent P; Reboul F

Clinique Sainte-Catherine, Avignon, France.

Cancer Radiother 1998 Apr;2 Suppl 1:77s-81s PMID: 9749084 UI: 98420908
7. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. Shipley WU; Winter KA; Kaufman DS; Lee WR; Heney NM; Tester WR; Donnelly BJ; Venner PM; Perez CA; Murray KJ; Doggett RS; True LD Department of Radiation Oncology, Massachusetts General Hospital, Boston 02114, USA.

8. Combined Modality Treatment with Selective Bladder Conservation for Invasive Bladder Cancer: Long-Term Tolerance in the Female Patient Kachnic LA; Shipley WU; Griffin PP; Zietman AL; Kaufman DS; Althausen AF; Heney NM
Genitourinary Oncology Unit, Departments of Radiation Oncology, Urology, and Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston,
Against Bladder Sparing


5. Commentary at the end of article in reference #1; Harry W. Herr Urology Service, Department of Surgery Memorial Sloan-Kettering Cancer Center New York, New York

Radiation

1. 8th European Urological Winter Forum, Davos, Switzerland Feb.-21-25, 1999
Talk by Dr. Mundy, expert urologist from the UK, reviewed on www.uroweb.nl
http://www.uroweb.nl/highlights/davos99/body.shtml by Drs. Volkan Ulker and Henk van der Poel


5. Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital with cancer-centre status. Bell CR; Lydon A; Kernick V; Hong A; Penn C; Pocock RD; Stott MA Br J Urol 1999 Apr;83(6):613-618 PMID: 10233566 UI: No Cit. ID assigned


8. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Lara PC; Rey A; Santana C; Afonso JL; Diaz JM; Gonzalez GJ; Apolinario R. Department of Radiation Oncology, Hospital Nuestra Senora del Pino, Las Palmas de Gran Canaria, Spain. Radiother Oncol 1998 Nov;49(2):163-7 PMID: 10052882 UI: 99160247


10. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Chyle V; Pollack A;

Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland. Acta Oncol 1990;29(7):909-14
PMID: 2261207 UI: 91084017

12. Survival after radical treatment for transitional cell carcinoma of the bladder. Daehlin L; Haukaas S; Maartmann-Moe H; Medby PC
PMID: 10188858 UI: 99202741

13. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. Gospodarowicz MK; Hawkins NV; Rawlings GA; Connolly JG; Jewett MA; Thomas GM; Herman JG; Garrett PG; Chua T; Duncan W; et al
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. J Urol 1989 Dec;142(6):1448-53; discussion 1453-4
PMID: 2585617 UI: 90064839

Hyperthermia


Dunst J; Sauer R; Schrott KM; Kuhn R; Wittekind C; Altendorf-Hofmann A
Department of Radiotherapy, University of Erlangen, Germany

5. Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital with cancer-centre status.
6. Good results of bladder-preserving treatment in poorly differentiated and invasive bladder
carcinoma using interstitial Iridium-192 radiotherapy Moonen LM; Horenblas S; Pos F; Schaefer
BS; Meinhardt W; Bartelink H Afd. Radiotherapie, Nederlands Kanker Instituut/Antoni van
8766684 UI: 96339152

7. Muscle invasive bladder cancer treated by transurethral resection, followed by external beam
radiation and interstitial iridium-192.
Wijnmaalen A; Helle PA; Koper PC; Jansen PP; Hanssens PE; Boeken Kruger CG; van Putten WL
Department of Radiation Oncology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The

8. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients
treated by radical radiation therapy. Lara PC; Rey A; Santana C; Afonso JL; Diaz JM; Gonzalez GJ;
Apolinario R Department of Radiation Oncology, Hospital Nuestra Senora del Pino, Las Palmas de

9. Apoptosis in carcinoma of the bladder: relation with radiation treatment results. Lara PC; Perez
S; Rey A; Santana C Department of Radiation Oncology, Hospital Nuestra Senora del Pino, Las
10192349 UI: 992065678

10. Apoptosis and downstaging after preoperative radiotherapy for muscle- invasive bladder
cancer Chyle V; Pollack A; Czerniak B; Stephens LC; Zagars GK; Terry NH; Meyn RE Department
of Radiotherapy, University of Texas, M.D. Anderson Cancer Center, Houston, 77030, USA. Int J
Radiat Oncol Biol Phys 1996 May 1;35(2):281-7 PMID: 8635934 UI: 96228841


13. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. Gospodarowicz MK; Hawkins NV; Rawlings GA; Connolly JG; Jewett MA; Thomas GM; Herman JG; Garrett PG; Chua T; Duncan W; et al Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. J Urol 1989 Dec;142(6):1448-53; discussion 1453-4 PMID: 2585617 UI: 90064839

14. CANCER FACTS National Cancer Institute National Institutes of Health http://www.vci.org/ Valley Cancer Institute in California, holistic center using hyperthermia alone or combined with radiation and chemotherapy.

15. A clinical survey of advanced bladder cancer: treatment of advanced and non-resectable bladder cancer Naito K; Hasegawa T; Ishida T; Yamamoto H; Mihara S; Komatsu K; Ueki O; Koshida K; Hisazumi H Department of Urology, School of Medicine, Kanazawa University. Hinyokika Kiyo 1991 Dec;37(12):1601-6 PMID: 1785381 UI: 92151847

16. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. Colombo R; Da Pozzo LF; Lev A; Salonia A; Rigatti P; Leib Z; Servadio C; Caldarera E; Pavone-Macaluso M Department of Urology, Scientific Institute H. San Raffaele, Milan, Italy. J Urol 1998 Mar;159(3):783-7 PMID: 9474148 UI: 98134423
17. Feasibility, toxicity, and preliminary results of weekly loco-regional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer.

Rietbroek RC; Bakker PJ; Schilthuis MS; Postma AJ; Zum Vorde Sive Vording PJ; Gonzalez Gonzalez D; Kurth KH; Bakker AJ; Veenhof CH

Department of Medical Oncology, Academic Medical Center, University of Amsterdam, The Netherlands. Int J Radiat Oncol Biol Phys 1996 Mar 1;34(4):887-93 PMID: 8598366 UI: 96175268

Muscle-invasive bladder cancer


http://www.ca-journal.org/articles/46/2/093-112/46_093-112_frame.htm

References used in Lamm and Torti’s article;


2. Radical cystectomy in the octogenarian.

Stroumbakis N; Herr HW; Cookson MS; Fair WR

Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. J Urol 1997 Dec;158(6):2113-7

PMID: 9366325 UI: 98031653

3. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial cancer: A cooperative group study. J Clin Oncol 15:2564-2569, 1997. Saxman SB; Propert KJ; Einhorn LH; Crawford ED; Tannock I; Raghavan D; Loehrer PJ Sr; Trump D


Lorusso V; Pollera CF; Antimi M; Luporini G; Gridelli C; Frassineti GL; Oliva C; Pacini M; De Lena M

Medical Oncology Division, Oncology Hospital, Bari, Italy


PMID: 9849481 UI: 99066343


7. Review and outlook for the role of paclitaxel in urothelial carcinoma

Vaughn DJ University of Pennsylvania Cancer Center, Philadelphia 19104, USA.

Semin Oncol 1999 Feb;26(1 Suppl 2):117-22PMID: 10190793 UI: 99205068

8. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Pycha A; Grbovic M; Posch B; Schnack B; Haitel A; Heinz-Peer G; Zielinski CC; Marberger M Department of Urology, University of Vienna, Austria.


10. (as reviewed in); http://www.ca-journal.org/articles/48/5/263-268/48_263-268_frame.htm

Bladder Cancer: Twenty Years of Progress and the Challenges That Remain. Donald L. Lamm, M.D. CAJournal for Clinicians, Guest Editorial 1998


11. http://www.mskcc.org/document/WICBLAD.htm Memorial Sloan Kettering Cancer Center

12. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. Logothetis C; Swanson D; Amato R; Banks M; Finn L; Ayala A; Ro J; Babaian R; Dinney C; Ellerhorst J; Hall C; von Eschenbach A.

Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. J Urol. 1996;155:1241-1245. PMID: 8632540 UI: 96230142

13. New chemotherapy regimens for advanced bladder cancer Fagbemi SO; Stadler WM

Department of Medicine, University of Chicago, IL 60637


14. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. Logothetis CJ; Hossan E; Recondo G; Sella A; Ellerhorst J; Kilbourn R; Zukowski A; Amato R Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.


Additional source;

Systemic Therapy for Invasive Bladder Cancer

Milind Javle, MD, and Derek Raghavan, MD, PhD, FRACP, FACP

http://www.moffitt.usf.edu/pubs/ccj/v3n6/a2.html

Gene therapy


2. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. Logothetis CJ; Xu HJ; Ro JY; Hu SX; Sahin A; Ordonez N; Benedict WF Department of Medical Oncology, University of
3. Accumulation of nuclear p53 and tumor progression in bladder cancer. Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ

Department of Urology, University of Southern California School of Medicine, Los Angeles 90033.


4. Dr. John D. Seigne Department of Urology at The University of Texas, M.D. Anderson Cancer Center, Houston, Tex. Dr. Seigne is now with the Department of Urology at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. Article "Gene Therapy for Bladder Cancer" CREDIT AND/OR COPYRIGHT NOTICE Reproduced by Permission from Cancer Control: Journal of the Moffitt Cancer Center http://www.moffitt.usf.edu/pubs/ccj/ 3(5):428-433, 1996. © 1996 Moffitt Cancer Center & Research Institute. Article also found at Medscape


Biomarkers

1. Cancer Prevention: The Roles of Diet and Chemoprevention; Peter Greenwald, MD, DrPH, Sharon S. McDonald, MS, Division of Cancer Prevention and Control at the National Cancer Institute, Bethesda, Md (PG) and The Scientific Consulting Group, Inc, Gaithersburg, Md (SSM) http://www.moffitt.usf.edu/pubs/ccj/v4n2/article2.html Paraphrased/excerpted with permission from Cancer Control: Journal of the Moffitt Cancer Center. The Moffit Journal can also be found on Medscape


4. Prognostic markers in bladder cancer: a contemporary review of the literature. Stein JP; Grossfeld GD; Ginsberg DA; Esrig D; Freeman JA; Figueroa AJ; Skinner DG; Cote RJ Department of Urology, Kenneth Norris, Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, USA. J Urol 1998;160(3 Pt 1):645-59 UI: 98385469

6. Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. Hemstreet GP 3rd; Rao J; Hurst RE; Bonner RB; Mellott JE; Rooker GMDepartment of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, USA. Cancer Detect Prev 1999;23(2):163-71 PMID: 10101598 UI: 99201814

7. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Lara PC; Rey A; Santana C; Afonso JL; Diaz JM; Gonzalez GJ; Apolinaro RDepartment of Radiation Oncology, Hospital Nuestra Senora del Pino, Las Palmas de Gran Canaria, Spain. Radiother Oncol 1998 Nov;49(2):163-7 PMID: 10052882 UI: 99160247


10. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Esrig D; Spruck CH 3d; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ

Urologic Cancer Research Laboratory, University of Southern California, Los Angeles 90033.


11. Two molecular pathways to transitional cell carcinoma of the bladder. Spruck CH 3rd; Ohneseit PF; Gonzalez-Zulueta M; Esrig D; Miyao N; Tsai YC; Lerner SP; Schmutte C; Yang AS; Cote R; et al Kenneth Norris Jr. Comprehensive Cancer Center, Department of Biochemistry and Molecular Biology, University of Southern California, School of Medicine, Los Angeles 90033. Cancer Res. 1994;54:784-788. PMID: 8306342 UI: 94138941

From; Cancer Control: Journal of the Moffitt Cancer Center; Pathology Update: Pathobiology of Preinvasive Urothelial NeoplasiaAuthor: Jose I. Diaz, MD, Pathology Service, H. Lee Moffitt Cancer Center & Research Institute 3(6):552-556, 1996. © 1996 Moffitt Cancer Center & Research Institute] Full article can be found at http://www.moffitt.usf.edu/pubs/ccj/v3n6/patholog.html Article can also be found at Medscape

12. David P. Lane FRS, FRSE, FRCPath, Ph.D.

Professor, Gibb Fellow of the CRC,

Director of the CRC Cell Transformation Group,

Department of Biochemistry,
The University of Dundee,
http://www.dundee.ac.uk/biochemistry/dpl.htm

13. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer Stein JP; Ginsberg DA; Grossfeld GD; Chatterjee SJ; Esrig D; Dickinson MG; Groshen S; Taylor CR; Jones PA; Skinner DG; Cote RJ Department of Pathology, University of Southern California School of Medicine and Kenneth Norris Jr. Comprehensive Cancer Center, Los Angeles 90033, USA. J Natl Cancer Inst 1998 Jul 15;90(14):1072-9 PMID: 9672255 UI: 98335999

14. Can p53 help select patients with invasive bladder cancer for bladder preservation?
Herr HW; Bajorin DF; Scher HI; Cordon-Cardo C; Reuter VE
Department of Surgery, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York, USA. J Urol 1999 Jan;161(1):20-2; discussion 22-3
PMID: 10037358 UI: 99154962

15. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer
Logothetis CJ; Xu HJ; Ro JY; Hu SX; Sahin A; Ordonez N; Benedict WF
Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030

16. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cote RJ; Dunn MD; Chatterjee SJ; Stein JP; Shi SR; Tran QC; Hu SX; Xu HJ; Groshen S; Taylor CR; Skinner DG; Benedict WF Department of Pathology, University of Southern California School of Medicine/Norris Comprehensive Cancer Center, Los Angeles 90033, USA. Cancer Res 1998 Mar 15;58(6):1090-4 PMID: 9515785 UI: 98175538

17. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells.
Miyake H; Hara I; Yamanaka K; Gohji K; Arakawa S; Kamidono S
Department of Urology, Kobe University School of Medicine, Japan.
Br J Cancer 1999 Apr;79(11-12):1651-6 PMID: 10206273 UI: 99221114

18. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer.
Miyake H; Hanada N; Nakamura H; Kagawa S; Fujiwara T; Hara I; Eto H; Gohji K; Arakawa S; Kamidono S; Saya H Department of Tumor Genetics and Biology, Kumamoto University School of Medicine, Honjo, Japan.
Oncogene 1998 Feb 19;16(7):933-43 PMID: 9484785 UI: 98143314
19. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder: implications and applications.

Benson MC; Giella J; Whang IS; Buttyan R; Hensle TW; Karp F; Olsson CA


20. Oncotech biotech laboraty

21. Expression of the multidrug resistance-associated protein (MRP) gene in urothelial carcinomas. Kubo H; Sumizawa T; Koga K; Nishiyama K; Takebayashi Y; Chuman Y; Furukawa T; Akiyama S; Ohi Y

Institute for Cancer Research, Faculty of Medicine, Kagoshima University, Japan.


22. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC Department of Urology, Erasme University Hospital, Brussels, Belgium. J Urol 1999 Mar;161(3):792-8 PMID: 10022686 UI: C

23. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette- Guerin therapy: correlation to clinical outcome. Lacombe L; Dalbagni G; Zhang ZF; Cordon-Cardo C; Fair WR; Herr HW; Reuter VE Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6356, USA.

PMID: 8874323 UI: 97028309

Other sources

Bladder Cancer: State of the Art Care Michael J. Droller M.D.


CCDRT drug resistance tests

1. In vitro chemosensitivity of human bladder cancer. Weisenthal LM; Lalude AO; Miller JB

Cancer 1983 Apr 15;51(8):1490-6 PMID: 6186358 UI: 83128909

3. High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Furukawa T; Kubota T; Watanabe M; Takahara T; Yamaguchi H; Takeuchi T; Kase S; Kodaira S; Ishibiki K; Kitajima M; et al Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.


DMSO


2. Interstitial Cystitus Foundation; http://www.ichelp.com/TreatmentAndSelfHelp/DMSO.html#General Information


5. Studies on enhancement of drug absorption through the bladder mucosa Sasaki M; Hashimoto H; Yachiku S

   Department of Urology, Asahikawa Medical College Nippon Hinyokika Gakkai Zasshi 1994 Sep;85(9):1353-62 PMID: 7967297 UI: 95056779

6. Transmurally absorbed intravesical chemotherapy with dimethylsulfoxide in an animal model [In Process Citation] Yaman O; Ozdiler E; Sozen S; Gogus O Department of Urology, University of Ankara, Turkey


7. Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with

Chemoprevention

1. Cancer Prevention: the Roles of Diet and Chemoprevention. Peter Greenwald, MD, DrPH, Sharon S. McDonald, MS, Division of Cancer Prevention and Control at the National Cancer Institute, Bethesda, Md (PG) and The Scientific Consulting Group, Inc, Gaithersburg, Md (SSM). Article also found on www.medscape.com

2. Ethical Issues of Chemoprevention Clinical Trials. Victor G. Vogel, MD, MHS, University of Pittsburgh Cancer Institute, Pittsburgh, Pa (VGV), Lisa S. Parker, PhD, Department of Human Genetics at the University of Pittsburgh (LSP). Article also found at: www.medscape.com

Fluids

1. Fluid intake and the risk of bladder cancer in men. Michaud DS; Spiegelman D; Clinton SK; Rimm EB; Curhan GC; Willett WC; Giovannucci EL. Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA. N Engl J Med 1999 May 6;340(18):1390-7

Urinary pH


1. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group. Aso Y; Akazan H Department of Urology, Faculty of Medicine, University of Tokyo, Japan.


Nutrition


Peter Greenwald, MD, DrPH, Sharon S. McDonald, MS, Division of Cancer Prevention and Control at the National Cancer Institute, Bethesda, Md (PG) and The Scientific Consulting Group, Inc, Gaithersburg, Md (SSM)

Article also found on www.medscape.com

CREDIT AND/OR COPYRIGHT NOTICE

Reproduced by Permission from Cancer Control: Journal of the Moffitt Cancer Center http://www.moffitt.usf.edu/pubs/ccj/


John Anderson, M.D.

Used with permission.

3. Michaud DS; Spiegelman D; Clinton SK; Rimm EB; Willett WC; Giovannucci EL

Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA. hpds@gauss.bwh.harvard.edu

J Natl Cancer Inst 1999 Apr 7;91(7):605-13

PMID: 10203279 UI: 99217942


Giovannucci E Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. J Natl Cancer Inst 1999 Feb 17;91(4):317-31 PMID: 10050865 UI: 99158152

Oncovite

2. DL Lamm; unpublished comments

Vitamins/antioxidants


Article by John Anderson, M.D. Natual Pharmacy

2. Rusty Morgan

3. Guidelines for use of Ascorbic acid in the prevention and treatment of cancer

http://www.bccancer.bc.ca British Columbia Cancer Agency (last revised Jan. '98)

Additional sources quoted in the BC Guide;

Adler T Power foods: looking at how nutrients may fight cancer.


Oltipraz


Peter Greenwald, MD, DrPH, Sharon S. McDonald, MS, Division of Cancer Prevention and Control at the National Cancer Institute, Bethesda, Md (PG) and The Scientific Consulting Group, Inc, Gaithersburg, Md (SSM)